CTSO Cytosorbents (CTSO) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001175151
Cluster · 4 insidersC-suite buying · 3
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
19
13F, latest reported quarter
What the filings say about CTSO
Insiders, 180 days
+$269.3K net bought
4 buyers
Cytosorbents insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Cytosorbents Corp insiders bought a net $269.3K of stock across 55 Form 4 purchases and sales, with 4 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Dec 13, 2023.
- -23.7% median (-23.7% mean) 90-day return after 2 previous buys.
- The trade is 20.5% of the 9,287 shares held after it.
- 2 other insiders bought within 30 days.
- 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sobel Alan D. bought about $11.6K of CTSO on Sep 15, 2026; 2 other insiders bought within 30 days and 19 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Dec 13, 2023.
- -23.7% median (-23.7% mean) 90-day return after 2 previous buys.
- The trade is 5.1% of the 9,787 shares held after it.
- 2 other insiders bought within 30 days.
- 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sobel Alan D. bought about $3.0K of CTSO on Sep 15, 2026; 2 other insiders bought within 30 days and 19 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Dec 13, 2023.
- -23.7% median (-23.7% mean) 90-day return after 2 previous buys.
- The trade is 1.0% of the 9,887 shares held after it.
- 2 other insiders bought within 30 days.
- 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sobel Alan D. bought about $601 of CTSO on Sep 15, 2026; 2 other insiders bought within 30 days and 19 funds added in the latest 13F quarter.Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 buys), the last on Sep 4, 2026.
- -10.6% median (+264.3% mean) 90-day return after 12 previous buys.
- The trade is 3.7% of the 100,996 shares held after it.
- 2 other insiders bought within 30 days.
- 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Chan Phillip P. bought about $22.6K of CTSO on Sep 15, 2026; 2 other insiders bought within 30 days and 19 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Dec 13, 2023.
- -3.0% median (-11.1% mean) 90-day return after 4 previous buys.
- The trade is 4.5% of the 40,114 shares held after it.
- 2 other insiders bought within 30 days.
- 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and COO Capponi Vincent bought about $10.9K of CTSO on Sep 14, 2026; 2 other insiders bought within 30 days and 19 funds added in the latest 13F quarter.55 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$269.3K over 180 days
+$120.4K over 90 days
more than 81% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
19 funds bought in last quarter
below 73% of Medical Devices
Revenue
+4.1% year over year
below 67% of Medical Devices
Margin
-22.1% net margin
below 55% of Medical Devices
Buybacks
no share repurchases reported
Short interest
4.1% of the float short (float per yahoo 2026-10-27) · 10.3 days to cover · settled 2026-10-15
below 83% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CTSO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+430.9%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CTSO: institutional holders (13F)
13F holdings, latest reported quarter
5,189,218 sh
$1.9M
1,968,691 sh
$740.5K
1,914,063 sh
$715.9K
1,476,500 sh
$552.2K
1,211,400 sh
$453.1K
Congress trades in CTSO
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CTSO planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CTSO mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Neuberger Intrinsic Value Fund
$317.4K position · as of 2026-05-31
0.0%
Morgan Stanley Pathway Small-Mid Cap Equity ETF
$10.7K position · as of 2026-05-31
0.0%
Fidelity Extended Market Index Fund
$186.7K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$214.8K position · as of 2026-06-30
0.0%
Column Small Cap Fund
$1.0K position · as of 2026-05-31
0.0%
Column Small Cap Select Fund
$3.3K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 2
0 active
6
Not applicable
2 active
What changed recently
Safe and Timely Antithrombotic Removal (STAR) Registry
2026-10-22 · Completion moved 2025-09-30 → 2030-09-30
,
Safe and Timely Antithrombotic Removal (STAR) Registry
2026-10-22 · Recruiting → Active Not Recruiting
,
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
4 insiders reported buying shares.
The record shows a net $269.3K bought by insiders over 180 days, 19 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CTSO financials
Revenue growth
+4.1%
XBRL, annual
Net margin
-22.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$37.2M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CTSO
| FY Dec 2025 | $37.1M |
| FY Dec 2024 | $35.6M |
| FY Dec 2023 | $36.3M |
| FY Dec 2022 | $34.7M |
| FY Dec 2021 | $43.2M |
| Jun 2026 | $9.6M |
| Mar 2026 | $8.9M |
| Dec 2025 | $9.2M |
| Sep 2025 | $9.5M |
| Jun 2025 | $9.6M |
| Mar 2025 | $8.7M |
| Dec 2024 | $6.5M |
| Sep 2024 | $9.4M |
At each fiscal year end
Single quarter
Net margin, TTM
-48.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CTSO
| FY Dec 2025 | -22.1% |
| FY Dec 2024 | -58.2% |
| FY Dec 2023 | -80.5% |
| FY Dec 2022 | -94.6% |
| FY Dec 2021 | -56.9% |
| Jun 2026 | -45.9% |
| Mar 2026 | -57.9% |
| Dec 2025 | -59.5% |
| Sep 2025 | -33.4% |
| Jun 2025 | +20.2% |
| Mar 2025 | -16.9% |
| Dec 2024 | -116.0% |
| Sep 2024 | -29.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$9.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CTSO
| FY Dec 2025 | -$12.5M |
| FY Dec 2024 | -$14.7M |
| FY Dec 2023 | -$22.2M |
| FY Dec 2022 | -$34.3M |
| FY Dec 2021 | -$17.6M |
| Jun 2026 | -$597.0K |
| Mar 2026 | -$1.2M |
| Dec 2025 | -$4.9M |
| Sep 2025 | -$2.6M |
| Jun 2025 | -$1.5M |
| Mar 2025 | -$3.5M |
| Dec 2024 | -$2.4M |
| Sep 2024 | -$2.6M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity CTSO
| FY Dec 2025 | 3.25x |
| FY Dec 2024 | 1.49x |
| FY Dec 2023 | 0.21x |
| FY Dec 2022 | 0.14x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | n/a |
| Mar 2026 | 7.73x |
| Dec 2025 | 3.25x |
| Sep 2025 | 1.89x |
| Jun 2025 | 1.46x |
| Mar 2025 | 1.15x |
| Dec 2024 | 1.49x |
| Sep 2024 | 1.22x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.53x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt CTSO
| FY Dec 2025 | -0.65x |
| FY Dec 2024 | -0.87x |
| FY Dec 2023 | -4.29x |
| FY Dec 2022 | -5.65x |
| FY Dec 2021 | n/a |
| Jun 2026 | -0.53x |
| Mar 2026 | -0.59x |
| Dec 2025 | -0.65x |
| Sep 2025 | -0.58x |
| Jun 2025 | -0.58x |
| Mar 2025 | -0.78x |
| Dec 2024 | -0.87x |
| Sep 2024 | -1.13x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-336.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CTSO
| FY Dec 2025 | -96.4% |
| FY Dec 2024 | -119.8% |
| FY Dec 2023 | -99.4% |
| FY Dec 2022 | -67.0% |
| FY Dec 2021 | -34.6% |
| Jun 2026 | -336.2% |
| Mar 2026 | -141.6% |
| Dec 2025 | -96.4% |
| Sep 2025 | -91.7% |
| Jun 2025 | -68.0% |
| Mar 2025 | -94.3% |
| Dec 2024 | -119.8% |
| Sep 2024 | -122.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-42.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CTSO
| FY Dec 2025 | -17.9% |
| FY Dec 2024 | -41.3% |
| FY Dec 2023 | -50.3% |
| FY Dec 2022 | -43.0% |
| FY Dec 2021 | -27.4% |
| Jun 2026 | -42.4% |
| Mar 2026 | -25.9% |
| Dec 2025 | -17.9% |
| Sep 2025 | -22.0% |
| Jun 2025 | -19.5% |
| Mar 2025 | -32.9% |
| Dec 2024 | -41.3% |
| Sep 2024 | -41.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital CTSO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-49.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CTSO
| FY Dec 2025 | -41.0% |
| FY Dec 2024 | -43.0% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -48.7% |
| FY Dec 2021 | -29.2% |
| Jun 2026 | -49.6% |
| Mar 2026 | -42.6% |
| Dec 2025 | -41.0% |
| Sep 2025 | -36.6% |
| Jun 2025 | -38.4% |
| Mar 2025 | -41.6% |
| Dec 2024 | -43.0% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CTSO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$293.7M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value CTSO
| FY Dec 2025 | $53.0M |
| FY Dec 2024 | $63.0M |
| FY Dec 2023 | $40.2M |
| FY Dec 2022 | $50.5M |
| FY Dec 2021 | $130.0M |
| Jun 2026 | $36.3M |
| Mar 2026 | $47.6M |
| Dec 2025 | $53.0M |
| Sep 2025 | $68.2M |
| Jun 2025 | $86.8M |
| Mar 2025 | $67.6M |
| Dec 2024 | $63.0M |
| Sep 2024 | $92.3M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-3.3%
TTM free cash flow over market value at close 2026-10-26
FCF yield CTSO
| FY Dec 2025 | -31.2% |
| FY Dec 2024 | -29.6% |
| FY Dec 2023 | -45.0% |
| FY Dec 2022 | -50.7% |
| FY Dec 2021 | -9.7% |
| Jun 2026 | -39.6% |
| Mar 2026 | -28.9% |
| Dec 2025 | -31.2% |
| Sep 2025 | -17.1% |
| Jun 2025 | -12.5% |
| Mar 2025 | -21.3% |
| Dec 2024 | -29.6% |
| Sep 2024 | -23.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CTSO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $37.1M | $35.6M | $36.3M | $34.7M |
| Gross profit | $26.5M | $24.9M | $22.0M | $20.7M |
| Operating income | -$14.7M | -$16.5M | -$31.9M | -$31.5M |
| Net income | -$8.2M | -$20.7M | -$29.2M | -$32.8M |
| EPS (diluted) | -0.13 | -0.38 | -0.65 | -0.75 |
| Operating cash flow | -$12.4M | -$14.4M | -$21.7M | -$28.2M |
| Cash | $6.2M | $3.3M | $14.1M | $22.1M |
| Long-term debt | $16.7M | $14.0M | $2.5M | $5.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
CTSO Stock Sonar score 6/7 axes
Find similar shapesCompareCTSO ranks highest on insider conviction (86th percentile) and financial health (42nd), and lowest on profitability (25th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CTSO filings, in plain words
Are Cytosorbents insiders buying or selling CTSO?
In the 180 days to 2026-10-28, Cytosorbents insiders were net buyers, a net $269.3K across purchases and sales reported on Form 4, by 4 buyers.
Read the full summary
In the 180 days to 2026-10-28, Cytosorbents insiders were net buyers of CTSO, a net $269.3K across purchases and sales reported on Form 4 by 4 buyers. 3 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
